March 06, 2026 17:33 ET | Source: Tango Therapeutics Sub, Inc BOSTON, March 06, 2026 (GLOBE NEWSWIRE) -- Tango Therapeutics,…
Aurora, CO, March 06, 2026 (GLOBE NEWSWIRE) -- This article is for informational purposes only. It is not medical advice.…
Spearfish, SD, March 06, 2026 (GLOBE NEWSWIRE) -- This article is an informational consumer research report and does not constitute…
OCALA, Fla., March 06, 2026 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) – AIM ImmunoTech Inc. (“AIM” or…
March 06, 2026 18:15 ET | Source: Lisata Therapeutics, Inc. Each Lisata stockholder to receive $5.00 per share in cash…
Positive results from Phase 3 ADAPT OCULUS study show VYVGART’s potential as the first targeted treatment for patients living with…
Regulated informationNazareth (Belgium)/Rotterdam (The Netherlands), 6 March 2026 7AM CET Fagron publishes its Annual Report 2025 Fagron, the leading global…
Tukwila, WA, March 05, 2026 (GLOBE NEWSWIRE) -- This report examines publicly available marketing statements and published research literature. Where…
ZUG, Switzerland, March 05, 2026 (GLOBE NEWSWIRE) -- Oculis Holding AG (Nasdaq: OCS; XICE: OCS) (“Oculis” or the “Company”), a…
ZUG, Switzerland, March 05, 2026 (GLOBE NEWSWIRE) -- Following the Company‘s press release published on March 3, the audited consolidated…